Source: International Congress 2018 – Lung cancer: from the bench to the bedside
Disease area: Thoracic oncology



Rating:

Share or cite this content

Citations should be made in the following way:
K. Syrigos (Athens, Greece), I. Kotteas (Athens, Greece), M. Paraskeva (Athens, Greece), I. Gkiozos (Athens, Greece), P. Boura (Athens, Greece), S. Tsagouli (Athens, Greece), D. Grapsa (Athens, Greece), A. Charpidou (Athens, Greece). Prognostic  value of  EGFR  genotype  in  EGFR-mutant  non-small  cell lung  cancer. 2852

Member's Comments

No comment yet.

Related content which might interest you: Prognostic value of ERCC1 expression in advanced non-small cell lung cancer (NSCLC) Source: Annual Congress 2012 - Prognosis of lung cancer Year: 2012 Characterization of patients with non-small cell lung cancer (NSCLC) relative to its EGFR mutational status Source: Annual Congress 2011 - Epidemiology of lung cancer and screening Year: 2011 Prognostic factors in non-small cell lung cancer Source: European Multidisciplinary Conference in Thoracic Oncology 2009 Year: 2009 Prognostic value of apoptotic index in non-small cell lung cancer Source: Eur Respir J 2004; 24: Suppl. 48, 5s Year: 2004 Progression after osimertinib in EGFR T790M-mutated non-small cell cancer patients Source: Virtual Congress 2020 – Real-world data and registries of thoracic oncology Year: 2020 Prognostic value of p21 protein expression in non-small cell lung cancer Source: Eur Respir J 2004; 24: Suppl. 48, 674s Year: 2004 Prognostic value of Her2/neu in stage IIIA non-small cell lung cancer Source: Eur Respir J 2006; 28: Suppl. 50, 770s Year: 2006 Prognostic value of comorbidity in operated non-small cell lung cancer Source: Eur Respir J 2006; 28: Suppl. 50, 763s Year: 2006 Prognostic value of integrated FDG-PET/CT in non-small cell lung cancer Source: Annual Congress 2008 - New imaging techniques in chest imaging Year: 2008 Prognostic factors for unresectable non-small cell lung cancer Source: Eur Respir J 2002; 20: Suppl. 38, 270s Year: 2002 Clinical relevance of p53 and K-ras mutations in nonsmall cell lung cancer (NSCLC) Source: Eur Respir J 2001; 18: Suppl. 33, 230s Year: 2001 Management of EGFR mutated nonsmall cell lung carcinoma patients Source: Eur Respir J 2015; 45: 1132-1141 Year: 2015 Ki-67 in non-small cell lung cancer Source: Annual Congress 2012 - New results in molecular pathology and functional genomics of neoplastic and non-neoplastic lung disease Year: 2012 How to treat brain metastasis in patients with non-small cell lung carcinoma (NSCLC) and EGFR mutations Source: International Congress 2015 – How to treat brain metastases Year: 2015 Investigation of survivin gene polymorphism in non-small cell lung cancer patients (NSCLC) Source: Annual Congress 2012 - New biomarkers for lung cancer Year: 2012 Prognostic value of TP53, KRAS and EGFR mutations in nonsmall cell lung cancer: the EUELC cohort Source: Eur Respir J 2012; 40: 177-184 Year: 2012 Our experience with crizotinib in the treatment of non-small cell lung cancer Source: Virtual Congress 2020 – Prognostic and predictive factors: treatment of lung cancer Year: 2020 p53 and mdm2 expression in nonsmall cell lung cancer (NSCLC): the lack of prognostic relevance Source: Eur Respir J 2001; 18: Suppl. 33, 230s Year: 2001 Risk factor for survival in never-smokers non-small cell lung cancer (NSCLC) Source: Annual Congress 2010 - Thoracic malignancies: interesting case studies and series Year: 2010 Prognostic significance of Nestin in resected non-small cell lung cancer Source: Annual Congress 2010 - Biomarkers for lung cancer Year: 2010